Overview

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

Status:
Completed

Trial end date:
2017-02-14

Target enrollment:

Participant gender:

Summary

There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed. Thus, the investigators are investigating the role of cellular immunity and immune escape mechanisms to explain the differential clinical response to cetuximab.

Phase:

Phase 2

Details

Lead Sponsor:

Robert Ferris
University of Pittsburgh

Collaborator:

Bristol-Myers Squibb

Treatments:

Carboplatin
Cetuximab
Cisplatin